Drug Profile
Research programme: protease inhibitors - Spexis
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Polyphor
- Developer Polyphor; Spexis
- Class Peptides; Small molecules
- Mechanism of Action Cysteine endopeptidase inhibitors; Leucocyte elastase inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency; Chronic obstructive pulmonary disease; Cystic fibrosis
- Discontinued Asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Switzerland (Inhalation, Aerosol)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Switzerland (Inhalation, Aerosol)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Switzerland (Inhalation, Aerosol)